Apheresis is the process of extracting one or more blood components from blood using an Apheresis system. The remaining components are then returned to the donor or patient during or after the process. The key factors driving the global Apheresis Market are increased demand for blood components globally and government blood donation initiatives. The worldwide apheresis market in 2021 was $1.79 billion and will be worth $3.87 billion by 2030, growing at a 7.78% CAGR from 2021-2030.


Growth Factors


The rising pervasiveness of syndromes, an increase in the demand for blood components and the safety that goes along with them, technological improvements in the creation of new apheresis techniques, and an increase in reimbursement policies and funding for apheresis procedures are the driving forces behind the growth of the apheresis market. For instance, NHS England has chosen the automated red blood cell exchange treatment carried out on the company’s Spectra Optia Apheresis System to treat sickle cell disease in June 2022 through the NHS MedTech Funding Mandate (MTFM). This decision will lead to greater use of Spectra Optia in hospitals across England. Now, sickle cell disease patients will have easier access to this treatment. As a result, rising funding initiatives for apheresis propel market growth.


Restraining Factors


The rising prevalence of various disorders and diseases such as Waldenstrom’s macroglobulinemia, growth of germ cell tumors from stem cells of the germ line and early embryo, Myasthenia gravis, Paraproteinemia, Cryoglobulinemia, Goodpasture’s syndrome, symptomatic myeloma, Guillain-BarrĂ© syndrome, HyperviscositySyndromes, sarcom, amyloidosis, and non-Hodgkin are restricting the expansion of the market.


Key Opportunities


The use of therapeutic apheresis in pediatric treatment is also expected to contribute to market growth. It is a technologically difficult task to provide therapeutic apheresis to children. The majority of apheresis therapies are the result of adult patient studies and trials. However, as the prevalence of diseases such as leukemia and autoimmune disorders among children rises, more efforts toward developing new apheresis treatment methods designed specifically for children will serve as a potential market opportunity.


Segmentation analysis


Product Insights


Based on product, disposables and reagents generated the most revenue in 2020, and it will continue throughout the forecasted period. Furthermore, during the forecasted period, the centrifugal apheresis devices category is expected to grow at the fastest CAGR. Because of the advantages of centrifugation over other methods and its efficiency in distinguishing all types of blood components, the market for centrifugal apheresis devices is expanding.


End-use Insights


In 2020, the market segment of blood collection centers and blood component providers held 67.5 percent of the global market. It is because of an increase in the number of blood component testing devices, an increase in the number of blood centers, and increased public awareness of blood collection centers.


Application Insights


In 2020, plasma apheresis accounted for nearly 50.0 percent of the market, holding the largest market share. Grifols advanced plasma apheresis in 1951 to discrete plasma from blood cells. The primary growth drivers for the market are the increasing prevalence of blood-related diseases and the rising demand for therapies derived from plasma.


Technology Insights


The centrifugation process held the largest market share and will rule throughout the anticipated time frame. This is because blood components like pack red blood cells (PRBCs) and fresh frozen plasma are frequently prepare using heavy spinning and centrifugation (FFP). Since membrane filters are necessary for separating plasma from other cellular components to achieve precise cell separation, membrane separation is predict to grow faster over the projected period.


Regional Insights


The market is divide into four regions on the basis of geography: Latin America, the Middle East, and Africa, Asia Pacific, Europe, and North America. In terms of revenue, the North American region dominated the global apheresis market in 2021. The primary factors driving the market’s growth in North America are the rising incidence of blood-related illnesses like kidney disease, cancer, and neurological disorders and the presence of developed healthcare infrastructure, and high patient awareness levels. The Centers for Disease Control and Prevention found that 37 million (15%) Americans have chronic kidney disease (CKD).


Key players analysis


  • Terumo BCT
  • Asahi Kasei Medical
  • Nikkiso
  • HemaCare Corporation
  • B. Braun Melsungen AG
  • Kaneka Corporation
  • Kawasumi Laboratories
  • Other Players

Leave a Reply